VJ/OA Oncology Journal Club: SANO Trial with Dr. van der Wilk (Oesophageal Cancer)

Dr. van der Wilk dives into the results of the SANO Trial in Oesophageal Cancer and recently published on the Lancet Oncology. 

The phase 3 trial investigated whether active surveillance could be a non-inferior alternative to standard surgery in individuals with oesophageal cancer who achieved a clinical complete response after neoadjuvant chemoradiotherapy. Conducted in 12 Dutch hospitals, the study randomized 309 participants to either active surveillance or standard oesophagectomy. After a median follow-up of 38 months, the 2-year overall survival for active surveillance (74%) was non-inferior to that of standard surgery (71%), with no significant differences in postoperative complications or mortality between groups. These results suggest active surveillance could be a viable option for patient counseling and shared decision-making, although extended follow-up is needed to assess long-term efficacy.